RT-qPCR-Based sgRNA Residual Detection

RT-qPCR-Based sgRNA Residual Detection

1. Technical Background

With the accelerating clinical translation of gene-editing technologies, regulatory agencies are imposing increasingly stringent safety evaluation requirements on gene-editing component residuals. The FDA guidance document Human Gene Therapy Products Incorporating Human Genome Editing explicitly requires minimization of the functional activity duration of gene-editing components. China's CDE guidance documents, the Technical Guidelines for Non-Clinical Research and Evaluation of Gene Therapy Products and the Technical Guidelines for Pharmacological Research and Evaluation of In Vivo Gene Therapy Products, both emphasize the need for rigorous detection and control of residuals from editing tools such as sgRNA.

As a process-related impurity, sgRNA's potential immunogenicity and sustained editing activity may affect the safety and efficacy of therapy. In the current regulatory environment, precise quantification of sgRNA residuals has become a mandatory requirement for regulatory submissions of gene-editing products.

2. ZhuHai GeneRulor RT-qPCR sgRNA Residual Detection: Technical Advantages and Workflow

2.1 Core Technical Advantages

(1) Absolute quantification technology ensuring detection precision: absolute quantification using standard curves is employed to obtain precise sgRNA copy numbers, with detection precision CV < 15%. Absolute quantification technology can provide accurate residual level data, meeting regulatory stringent requirements for quantification precision.

(2) Specific primer design effectively eliminating background interference: highly specific primers targeting the spacer and scaffold sequences are designed to effectively avoid interference from endogenous RNA. Primer design undergoes rigorous BLAST alignment analysis and experimental validation to ensure highly specific identification of the target sgRNA.

(3) Flexible detection strategies adaptable to multiple needs: supports both total sgRNA quantification and individual multi-site quantification detection modes. Total quantification is suitable for overall assessment of single-sgRNA systems, while individual multi-site quantification is adapted for refined analysis of complex gene-editing systems, meeting diverse research and regulatory needs.

(4) Cost-effective and suitable for large-scale applications: RT-qPCR technology demonstrates significant advantages in dynamic range and cost control, and is particularly well-suited for routine testing and large-scale sample processing.

2.2 Standardized Detection Workflow

(1) Sample processing and RNA extraction: specialized small RNA extraction kits optimized for the molecular characteristics of sgRNA are used to ensure maximum recovery. Compared with conventional total RNA extraction methods, small RNA-specific kits can significantly improve the recovery rate of short-chain RNA, providing a solid foundation for downstream detection.

(2) Specific reverse transcription: sgRNA-specific primers are used for the reverse transcription reaction; compared with random primers or universal primers, specific primers can significantly improve reverse transcription efficiency and detection specificity, reducing interference from non-specific products.

(3) Standard curve construction and quantitative detection: a standard curve covering 10²–10⁷ copies/μL is constructed, with linear correlation coefficient R² ≥0.99 and amplification efficiency 90–110%. SYBR Green real-time fluorescent quantitative PCR technology is employed to achieve precise quantification of sgRNA in samples.

(4) Data analysis and quality control: a comprehensive data analysis system is established, including standard curve fitting, sample copy number calculation, and quality control indicator assessment. Three technical replicates are set for each sample to ensure result reliability and reproducibility.

Figure 1. ZhuHai GeneRulor sgRNA residual detection workflow

2.3 Method Validation: Compliant with Regulatory Standards

Comprehensive method validation is conducted in strict accordance with ICH Q2(R1) guidelines and FDA Bioanalytical Method Validation guidance:

(1) Specificity validation: primer specificity for the target sgRNA is confirmed; BLAST alignment analysis validates absence of cross-reactivity, ensuring accurate and reliable detection results;

(2) Accuracy validation: recovery experiments demonstrate that spiking reference standards of known concentrations into negative samples achieves a recovery rate of 80–120%, meeting analytical method validation requirements;

(3) Precision validation: within-run repeatability CV < 10%; between-run intermediate precision CV < 15%, complying with regulatory agencies' strict precision requirements for detection methods;

(4) Linearity range validation: within the 10²–10⁷ copies detection range, linear correlation coefficient R² ≥0.99 and amplification efficiency 90–110%, ensuring the reliability of quantitative results;

(5) Limit validation: both the limit of detection (LOD) and limit of quantification (LOQ) are established to ensure the method's sensitivity meets practical detection needs.

3. sgRNA Residual Detection Application Scenarios (Full-Process R&D Support)

(1) IND submission support: provision of necessary sgRNA residual detection data for IND submissions of CAR-T cells, gene-editing therapeutics, and other cell-based gene therapy products, meeting the technical requirements of FDA, NMPA, and other regulatory agencies;

(2) Process optimization guidance: provision of data support for gene-editing process optimization through sgRNA residual monitoring at different time points, helping companies achieve the optimal balance between editing efficiency and safety, and reducing product development risk;

(3) Quality control applications: establishment of quality control standards for sgRNA residual detection to provide technical tools for product batch release and quality consistency evaluation.

4. sgRNA Residual Detection Service Content

* Service turnaround: standard workflow 8 business days (including extraction).

* Expedited service: 6 business days (including extraction) (+10% surcharge); 4 business days (including extraction) (+20% surcharge).

* Multi-site detection: for multi-site samples, individual site-specific detection service is provided to ensure independent accurate quantification for each site.

5. sgRNA Residual Detection Sample Requirements

* Notes: (1) All samples must meet the above standards to ensure the accuracy and reliability of detection results. (2) Clients may also submit pre-extracted small RNA; however, to ensure experimental performance, it is recommended to send cell pellet samples directly for RNA extraction by ZhuHai GeneRulor; cell pellet requirement: >1×10⁶ cells per site. (3) For special sample types, please contact the ZhuHai GeneRulor technical team in advance (Tel: 400-6309596; Order/Technical Support: service@generulor.com).

6. Quality Assurance and Technical Support

ZhuHai GeneRulor has established a comprehensive quality management system. Rigorous quality control standards are implemented for every testing batch to ensure the accuracy and reliability of detection results:

(1) Negative controls to ensure absence of contamination;

(2) Standard curve R² ≥0.99; amplification efficiency 90–110%;

(3) Technical replicate CV < 5%;

(4) Provision of detailed experimental reports and data analysis.

ZhuHai GeneRulor's professional technical team provides full-process technical consultation and develops customized detection plans based on the client's specific needs, ensuring that detection results comply with regulatory requirements and scientific standards.

Detailed experimental reports and data analysis are provided, including standard curve parameters, sample testing results, and quality control indicator assessment, delivering complete data support for clients' subsequent R&D and regulatory submission work.

7. References

China NMPA CDE Technical Guidance Documents:

[1] National Institutes for Food and Drug Control (NIFDC). Technical Guidelines for Non-Clinical Research and Evaluation of Gene Therapy Products (Trial). November 2021.

[2] National Institutes for Food and Drug Control (NIFDC). Technical Guidelines for Pharmacological Research and Evaluation of In Vivo Gene Therapy Products (Trial). May 2022.

[3] National Institutes for Food and Drug Control (NIFDC). Technical Guidelines for Cell Therapy Products.

[4] Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia, Volume IV.

FDA Regulatory Guidance Documents:

[5] FDA. Gene Therapy QC Testing Guidance.

[6] ICH. Q2(R1) Validation of Analytical Procedures: Text and Methodology.

Scientific Literature:

[7] Fujita E, Yamamoto S, Hanada T, et al. Using qPCR and ddPCR to study biodistribution of cell therapy products: a multi-site evaluation. Cytotherapy. 2025. Impact Factor: 3.2.

[8] Dang Y, Jia G, Choi J, et al. Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency. Genome Biology. 2015. Impact Factor: 10.1.